# MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

> **NCT03675139** · PHASE3 · COMPLETED · sponsor: **Xiaojun Chen** · enrollment: 471 (actual)

## Conditions studied

- Endometrial Hyperplasia Without Atypia

## Interventions

- **DRUG:** Medroxyprogesterone Acetate
- **DRUG:** Dydrogesterone 10 MG

## Key facts

- **NCT ID:** NCT03675139
- **Lead sponsor:** Xiaojun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-26
- **Primary completion:** 2022-05-14
- **Final completion:** 2022-05-15
- **Target enrollment:** 471 (ACTUAL)
- **Last updated:** 2023-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675139, "MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03675139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*